Delays in the dosing administration of PRRT in advanced neuroendocrine tumors – Is there an adverse impact?

#4114

Introduction: Peptide receptor radionuclide therapy (PRRT) has emerged as a major therapeutic component in the overall management of advanced neuroendocrine tumors (NETs). In Greece, the treatment has been performed for several years, however because of reimbursement issues, especially during the financial crisis in Greece, there is usually a delay between the administered doses beyond the recommended 6-8 weeks interval.

Aim(s): The aim of this study was to investigate the impact of treatment delays in the outcome of PRRTs.

Materials and methods: We collected retrospectively the data of patients who received PRRT from 2019 to 2022. Kaplan Mayer survival analysis was used for the estimation of median progression free survival (PFS) and overall survival (OS).

Conference:

Presenting Author:

Authors: Georgakopoulos A, Tsoli M, Koumarianou A, Papadopoulou N, Panagaki M,

Keywords: PRRT, Progression-free survival, overall survival,